Simplifying Global Compliance
Novartis Wins Advisory Panel Support for Approval of Tobi Alternative
Washington Drug Letter
The FDA’s Anti-Infective Drugs Advisory Committee has recommended the FDA approve Novartis’ inhaler-based version of cystic fibrosis (CF) drug Tobi.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing